ISA 2024 | Results of a study evaluating the predictive power of FISH markers for PFS in AL amyloidosis
Maximilian Steinhardt, MD, University Hospital Würzburg, Würzburg, Germany, outlines the results from a study looking into the progression-free survival (PFS) predictive power of FISH markers in plasma cells from patients with light chain (AL) amyloidosis. Using a retrospective approach, they sorted patients into two cohorts based on whether they could receive stem cell transplant (SCT) or not. The cohorts were comparable, and overall survival (OS) was similar between the two groups. This research demonstrates that FISH markers are able to predict for PFS in this patient population. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Travel funds from Janssen
